Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3Phase 3 2Phase 1/2 2

Status

Terminated 1Suspended 1Active not recruiting 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Head & Neck 1Dermatologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Melanoma 9Lung Neoplasms 5Colorectal Neoplasms 5Triple Negative Breast Neoplasms 3Rectal Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Colonic Neoplasms 3Thyroid Neoplasms 1Thyroid Diseases 1Spinocerebellar Degenerations 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Non-small Cell Carcinoma 1Neurofibromatosis 1 1Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Leukemia 1Hereditary Sensory and Autonomic Neuropathies 1Glioma 1Gastrointestinal Stromal Tumors 1Fallopian Tube Neoplasms 1Disease Progression 1Central Nervous System Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma 1Brain Neoplasms 1Brain Diseases 1Blast Crisis 1

Interventions

pembrolizumab 59Gemcitabine 37Biopsy 33Specimen Handling 32Paclitaxel 30Magnetic Resonance Spectroscopy 30Nivolumab 29Cisplatin 26Carboplatin 25Irinotecan 24Cyclophosphamide 23Fluorouracil 22Bevacizumab 22Docetaxel 21Oxaliplatin 19Leucovorin 18Ipilimumab 17Cetuximab 17Capecitabine 17130-nm albumin-bound paclitaxel 16Everolimus 15Albumin-Bound Paclitaxel 15Trastuzumab 13olaparib 12Pemetrexed 12Erlotinib Hydrochloride 12spartalizumab 11Sorafenib 11Radiosurgery 11trastuzumab deruxtecan 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Neoplasm Metastasis × binimetinib × Clear all
NCT05111561 2026-05-13

Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

National Cancer Institute (NCI)

Phase 1 Suspended
42 enrolled
Breast

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04913285 2026-04-27

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

Pierre Fabre Medicament

Phase 1 Active not recruiting
400 enrolled
DermatologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Thyroid Diseases

NCT04892017 2026-04-08

Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors

Deciphera Pharmaceuticals, LLC

Phase 1 Terminated
91 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡